SEC Form 4 · accession 0001193125-26-283138
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elena Ridloff
Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 25, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001815442
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $99.87 | Jun 24, 2026 | A | 6,068 | A | — | Jun 23, 2036 | Common Stock | 6,068 | 6,068 | D |
Explanation of responses
- F1The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.